MX2017015145A - Celulas madre derivadas de placenta para restaurar el motor regenerativo, corregir defectos proteomicos y extender la esperanza de vida. - Google Patents
Celulas madre derivadas de placenta para restaurar el motor regenerativo, corregir defectos proteomicos y extender la esperanza de vida.Info
- Publication number
- MX2017015145A MX2017015145A MX2017015145A MX2017015145A MX2017015145A MX 2017015145 A MX2017015145 A MX 2017015145A MX 2017015145 A MX2017015145 A MX 2017015145A MX 2017015145 A MX2017015145 A MX 2017015145A MX 2017015145 A MX2017015145 A MX 2017015145A
- Authority
- MX
- Mexico
- Prior art keywords
- stem cells
- subject
- restore
- extend
- proteomic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pregnancy & Childbirth (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
La invención actual se refiere al uso de células madre, tales como células madre derivadas de placenta (PDSC), para reducir los efectos del envejecimiento, restaurar el motor regenerativo y extender la esperanza de vida de sujetos envejecidos. Se proporcionan métodos para mantener o incrementar la relación del número de células madre al número de células diferenciadas en un tejido de un sujeto durante el tiempo, que comprende administrar al sujeto una cantidad efectiva de una población de células madre. Se proporcionan además métodos para mantener o incrementar el número de células madre en un tejido de un sujeto durante el tiempo, que comprende administrar al sujeto una cantidad efectiva de una población de células madre. También se proporcionan en la presente métodos para alterar el fenotipo o proteoma de una célula madre envejecida residente en un tejido de un sujeto, que comprende administrar al sujeto una cantidad efectiva de una población de células madre.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562167786P | 2015-05-28 | 2015-05-28 | |
| PCT/US2016/034773 WO2016191724A1 (en) | 2015-05-28 | 2016-05-27 | Placental-derived stem cells to restore the regenerative engine, correct proteomic defects and extend lifespan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017015145A true MX2017015145A (es) | 2018-08-01 |
Family
ID=57393743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017015145A MX2017015145A (es) | 2015-05-28 | 2016-05-27 | Celulas madre derivadas de placenta para restaurar el motor regenerativo, corregir defectos proteomicos y extender la esperanza de vida. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20160346333A1 (es) |
| EP (1) | EP3302065A4 (es) |
| JP (3) | JP2018520211A (es) |
| KR (2) | KR20180019613A (es) |
| CN (1) | CN107846903A (es) |
| AU (2) | AU2016267672A1 (es) |
| BR (1) | BR112017025586A2 (es) |
| CA (1) | CA2987064A1 (es) |
| CO (1) | CO2017013359A2 (es) |
| EA (1) | EA201792602A1 (es) |
| IL (1) | IL255920B2 (es) |
| MX (1) | MX2017015145A (es) |
| MY (1) | MY200016A (es) |
| NZ (1) | NZ737474A (es) |
| SG (1) | SG10201911206PA (es) |
| WO (1) | WO2016191724A1 (es) |
| ZA (1) | ZA201707905B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110809718A (zh) * | 2017-06-21 | 2020-02-18 | 韩国生命工学研究院 | 利用血液生物标志物诊断肌肉衰弱相关疾病的方法和试剂盒 |
| US20190369119A1 (en) * | 2018-06-04 | 2019-12-05 | Avon Products, Inc. | Protein Biomarkers for Identifying and Treating Aging Skin and Skin Conditions |
| JP2021531288A (ja) | 2018-07-22 | 2021-11-18 | ミノヴィア セラピューティクス リミテッド | 眼疾患のミトコンドリア増強療法 |
| US12551504B2 (en) | 2018-07-22 | 2026-02-17 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of pancreatic diseases |
| WO2020021536A1 (en) * | 2018-07-22 | 2020-01-30 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy for primary mitochondrial diseases |
| JP7524157B2 (ja) | 2018-07-22 | 2024-07-29 | ミノヴィア セラピューティクス リミテッド | 脳疾患のミトコンドリア増強療法 |
| US12329781B2 (en) | 2018-07-22 | 2025-06-17 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of renal diseases |
| KR102739453B1 (ko) | 2018-11-14 | 2024-12-09 | (주)아모레퍼시픽 | 피부 노화 모델의 제조방법, 그 방법에 의해 제조된 피부 노화 모델 및 그 피부 노화 모델을 이용한 항노화 물질의 스크리닝 방법 |
| CN109355393A (zh) * | 2018-12-12 | 2019-02-19 | 武汉凯德维斯生物技术有限公司 | 宫颈小细胞癌相关的hpv整合基因位点及其应用 |
| US20220160787A1 (en) * | 2019-03-15 | 2022-05-26 | Celularity Inc. | Placenta derived adherent cells for improved xenoplantation |
| CN109908323A (zh) * | 2019-04-01 | 2019-06-21 | 李胜 | 一种促成人体骨髓干细胞再生和激活休眠干细胞的复方制品制作方法 |
| CN110179827A (zh) * | 2019-06-27 | 2019-08-30 | 北京三有利和泽生物科技有限公司 | 牙源性间充质干细胞的应用 |
| CA3147962A1 (en) * | 2019-08-15 | 2021-02-18 | Steadman Philippon Research Institute | Methods for treating disease associated with senescence |
| CA3172402A1 (en) | 2020-03-31 | 2021-10-07 | Minovia Therapeutics Ltd. | Mitochondria-enriched genetically engineered cells and uses thereof |
| TWI761837B (zh) * | 2020-05-20 | 2022-04-21 | 國立中央大學 | 通用人類誘導多能性幹細胞及其生成方法 |
| CN112129877B (zh) * | 2020-09-24 | 2021-07-20 | 南京医科大学 | 精浆甘露糖-6-磷酸和新蝶呤检测作为特发性男性不育诊断标志物及其应用 |
| CN118176292A (zh) * | 2021-10-14 | 2024-06-11 | 北京干细胞与再生医学研究院 | 年轻化非多能性细胞及其制备方法和应用 |
| WO2023090901A1 (ko) * | 2021-11-18 | 2023-05-25 | 의료법인 성광의료재단 | 기계 학습을 이용한 세포 노화의 마커를 선별하는 방법, 세포 노화 바이오 마커, 및 이를 이용한 세놀리틱 제제를 스크리닝 하는 방법 |
| CN115927185B (zh) * | 2022-08-12 | 2025-05-02 | 中国医学科学院医药生物技术研究所 | 人过氧化物还原酶-5在诱导人脐带间充质干细胞向神经干细胞分化中的应用及诱导方法 |
| WO2024085637A1 (ko) * | 2022-10-18 | 2024-04-25 | 동국대학교 산학협력단 | 혈장 유래 단백질을 포함하는 노화 방지용 조성물 |
| CN115873804A (zh) * | 2023-01-06 | 2023-03-31 | 北京大学口腔医学院 | Bhlhe40基因在调控骨髓间充质干细胞增殖、分化和衰老中的应用 |
| CN118546871B (zh) * | 2024-05-10 | 2025-05-06 | 未来智人再生医学研究院(广州)有限公司 | 一种人多能干细胞分化为间充质干细胞的方法 |
| CN120860261B (zh) * | 2025-09-26 | 2026-01-09 | 山东大学齐鲁医院 | Angulin-1基因和/或Angulin-1蛋白在制备抗衰老及治疗衰老相关疾病的产品中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1218489B1 (en) * | 1999-09-24 | 2009-03-18 | Cybios LLC | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
| PL2471907T3 (pl) * | 2005-12-29 | 2019-07-31 | Celularity, Inc. | Populacje komórek macierzystych łożyska |
| US8562972B2 (en) * | 2006-10-23 | 2013-10-22 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
| CA2677679A1 (en) * | 2007-02-12 | 2008-08-21 | Anthrogenesis Corporation | Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations |
| NZ612888A (en) * | 2007-02-12 | 2015-02-27 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
| US9962409B2 (en) * | 2007-10-01 | 2018-05-08 | Vestion, Inc. | Therapy using cardiac stem cells and mesenchymal stem cells |
| CN101748096B (zh) * | 2008-12-17 | 2013-03-13 | 北京汉氏联合生物技术有限公司 | 亚全能干细胞、其制备方法及其用途 |
| ES2358146B1 (es) * | 2009-10-22 | 2012-03-23 | Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud En Sevilla | Uso de células mesenquimales nestina positivas para el mantenimiento de la hematopoyesis. |
-
2016
- 2016-05-27 CA CA2987064A patent/CA2987064A1/en active Pending
- 2016-05-27 EP EP16800824.1A patent/EP3302065A4/en not_active Withdrawn
- 2016-05-27 BR BR112017025586A patent/BR112017025586A2/pt not_active Application Discontinuation
- 2016-05-27 SG SG10201911206PA patent/SG10201911206PA/en unknown
- 2016-05-27 CN CN201680044147.8A patent/CN107846903A/zh active Pending
- 2016-05-27 JP JP2018514934A patent/JP2018520211A/ja active Pending
- 2016-05-27 US US15/167,696 patent/US20160346333A1/en not_active Abandoned
- 2016-05-27 WO PCT/US2016/034773 patent/WO2016191724A1/en not_active Ceased
- 2016-05-27 KR KR1020177037541A patent/KR20180019613A/ko not_active Ceased
- 2016-05-27 AU AU2016267672A patent/AU2016267672A1/en not_active Abandoned
- 2016-05-27 MX MX2017015145A patent/MX2017015145A/es unknown
- 2016-05-27 KR KR1020237033507A patent/KR20230145509A/ko not_active Ceased
- 2016-05-27 NZ NZ737474A patent/NZ737474A/en not_active IP Right Cessation
- 2016-05-27 MY MYPI2017704445A patent/MY200016A/en unknown
- 2016-05-27 IL IL255920A patent/IL255920B2/en unknown
- 2016-05-27 EA EA201792602A patent/EA201792602A1/ru unknown
-
2017
- 2017-11-21 ZA ZA2017/07905A patent/ZA201707905B/en unknown
- 2017-12-22 CO CONC2017/0013359A patent/CO2017013359A2/es unknown
-
2021
- 2021-05-13 AU AU2021203074A patent/AU2021203074A1/en not_active Abandoned
- 2021-07-01 JP JP2021110177A patent/JP2021165289A/ja active Pending
-
2023
- 2023-06-20 JP JP2023100474A patent/JP2023116745A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL255920A (en) | 2018-01-31 |
| AU2021203074A1 (en) | 2021-06-10 |
| JP2021165289A (ja) | 2021-10-14 |
| IL255920B1 (en) | 2024-01-01 |
| JP2018520211A (ja) | 2018-07-26 |
| AU2016267672A1 (en) | 2017-12-21 |
| SG10201911206PA (en) | 2020-01-30 |
| EP3302065A4 (en) | 2019-04-10 |
| BR112017025586A2 (pt) | 2018-08-07 |
| IL255920B2 (en) | 2024-05-01 |
| CO2017013359A2 (es) | 2018-03-28 |
| KR20230145509A (ko) | 2023-10-17 |
| CA2987064A1 (en) | 2016-12-01 |
| MY200016A (en) | 2023-12-04 |
| ZA201707905B (en) | 2018-11-28 |
| EP3302065A1 (en) | 2018-04-11 |
| EA201792602A1 (ru) | 2018-06-29 |
| CN107846903A (zh) | 2018-03-27 |
| WO2016191724A1 (en) | 2016-12-01 |
| JP2023116745A (ja) | 2023-08-22 |
| NZ737474A (en) | 2022-11-25 |
| KR20180019613A (ko) | 2018-02-26 |
| US20160346333A1 (en) | 2016-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017015145A (es) | Celulas madre derivadas de placenta para restaurar el motor regenerativo, corregir defectos proteomicos y extender la esperanza de vida. | |
| MX2016013963A (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
| MX339624B (es) | Composiciones mejoradas de celulas y metodos para preparar las mismas. | |
| CO2017005391A2 (es) | Composiciones de antibiótico | |
| ES2529378B1 (es) | Lente oftálmica multifocal y procedimiento para su obtención, mejorada | |
| MX356815B (es) | Composiciones y métodos para mejorar el estado bioenergético en células germinales femeninas. | |
| NI201100083A (es) | Compuestos que expanden células madre hematopoyéticas. | |
| BR112018014238A2 (pt) | composição e métodos para criopreservação de hutc | |
| MX2016004575A (es) | Metodos de modificacion de celulas huespedes. | |
| EA201690969A1 (ru) | Способы и композиции для лечения связанных со старением состояний | |
| CL2020002915A1 (es) | Composiciones para el tratamiento de condiciones de la piel | |
| MX356809B (es) | Animales no humanos que tienen un gen del factor activador de celulas b. | |
| MX2017016610A (es) | Metodos de reduccion de olor. | |
| MX2017005186A (es) | Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas. | |
| BR112016010191A2 (pt) | matriz de eluição e usos desta | |
| MX2018003678A (es) | Metodos moleculares de aseguramiento de la calidad para su uso en la secuenciacion. | |
| CL2015003402A1 (es) | Células madres adultas adiposas, humanas, pluripotentes: aislamiento, caracterización e implicaciones clinicas | |
| MX2021000322A (es) | Enzimas de variante fosfopentomutasa modificada geneticamente. | |
| MX376021B (es) | Composición que contiene norbixina para proteger las células del epitelio de pigmento de la retina. | |
| MX2015012341A (es) | Enriquecimiento de células tumorales circulantes por desgaste de glóbulos blancos. | |
| MX350158B (es) | Diacilhidrazina cristalina y sus usos. | |
| ES2514140B1 (es) | Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento | |
| DOP2016000079A (es) | Glicoproteinas recombinantes y sus usos | |
| BR112018014905A2 (pt) | método para determinar o envelhecimento de um meio de armazenamento eletroquímico | |
| MX376188B (es) | Composicion para reducir trastornos de envejecimiento de la piel que comprenden un retinaldehido y un extracto de leontopodium alpinum. |